Dermatologic management of oncotherapy side effects: A proposed algorithm.
cosmetologic algorithm
oncologic patient
skin reactions
Journal
Journal of cosmetic dermatology
ISSN: 1473-2165
Titre abrégé: J Cosmet Dermatol
Pays: England
ID NLM: 101130964
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
06
05
2020
revised:
13
06
2020
accepted:
17
06
2020
pubmed:
26
6
2020
medline:
15
5
2021
entrez:
26
6
2020
Statut:
ppublish
Résumé
Since the introduction of the first chemotherapeutic regimens for the treatment of oncological disease, hundreds of drugs have been approved for cancer treatment and many more are under investigation. The development of newer drugs such as target therapies, immuno-oncotherapies, and hormonal therapies has increased in specificity with the development of smaller molecules and more selective targets. Cutaneous side effects are now well known for both standard chemotherapy and targeted therapies. The correct diagnosis and management of these effects are of vital importance both to optimize therapeutic success rates and to reduce the patient's suffering. In fact, the appearance of a cutaneous adverse event can be responsible for a reduction in drug dosage or worse its suspension. In order to achieve this objective, we propose a management algorithm, based on three different steps, before, during, and after the oncological treatments, respectively. Our proposal underlines the importance of correct skin care measures to limit or reduce the severity of side effects.
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
429-436Informations de copyright
© 2020 Wiley Periodicals, LLC.
Références
Lacouture ME, Mitchell EP, Piperdi B, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28:1351-1357.
Peterson DE, Öhrn K, Bowen J, et al. Systematic review of oral cryotherapy for management of oral mucositis caused by cancer therapy. Support Care Cancer. 2013;21(1):327-332.
Stiff PJ, Emmanouilides C, Bensinger WI, et al. Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting. J Clin Oncol. 2006;24(33):5186-5193.
Bensadoun RJ, Nair RG. Low-level laser therapy in the prevention and treatment of cancer therapyinducedmucositis: 2012 state of the art based on literature review and meta-analysis. Curr Opin Oncol. 2012;24(4):363-370.
Migliorati C, Hewson I, Lalla RV, et al. Systematic review of laser and other light therapy for the management of oralmucositis in cancer patients. Support Care Cancer. 2013;21(1):333-341.
Rastogi M, Khurana R, Revannasiddaiah S, et al. Role of benzydamine hydrochloride in the prevention of oral mucositis in head and neck cancer patients treated with radiotherapy (>50 Gy) with or without chemotherapy. Support Care Cancer. 2017;25(5):1439-1443.
Donnelly JP, Bellm LA, Epstein JB, Sonis ST, Symonds RP. Antimicrobial therapy to prevent or treat oral mucositis. Lancet Infect Dis. 2003;3(7):405-412.
Breed WPM, Van der Hurk CJG, Peerbooms M. Presentation, impact and prevention of chemotherapy induced hair loss: scalp cooling potentials and limitations. Expert Rev Dermatol. 2011;6(1):109-125.
Macduff C, Mackenzie T, Hutcheon A, Melville L, Archibald H. The effectiveness of scalp cooling in preventive alopecia for patients receiving epirubicinand docetaxel. Eur J Cancer Care. 2003;12(2):154-161.
Fink M. Vitamin D deficiency is a cofactor of chemotherapy-induced mucocutaneous toxicity and dysgeusia. J Clin Oncol. 2011;29:e81-e82.
Arul Vijaya Vani S, Ananthanarayanan PH, Kadambari D, et al. Effects of vitamin D and calcium supplementation on side effects profile inpatients of breast cancer treated with letrozole. Clin Chim Acta. 2016;459:53-56.
National Cancer Institute. Common Terminology Criteria for Adverse Events v5.0. November 27, 2017.
Reyes-Habito CM, Roh EK. Cutaneous reactions to chemotherapeutic drugs and targeted therapies for cancer: part I. Conventional chemotherapeutic drugs. J Am Acad Dermatol. 2014;71(2):203.e1-203.e12.
Reyes-Habito CM, Roh EK. Cutaneous reactions to chemotherapeutic drugs and targeted therapy forcancer: Part II. Targeted therapy. J Am Acad Dermatol. 2014;71(217):e1-e11; quiz 27-8.
Shin H, Jo SJ, Kim DH, Kwon O, Myung SK. Efficacy of interventions for prevention of chemotherapy-induced alopecia: a systematic review and meta-analysis. Int J Cancer. 2015;136(5):E442-E454.
Rossi A, Caterina Fortuna M, Caro G, et al. Monitoring chemotherapy-induced alopecia with trichoscopy. J Cosmet Dermatol. 2019;18(2):575-580.
Gröber U, Holzhauer P, Kisters K, Holick M, Adamietz I. Micronutrients in Oncological Intervention. Nutrients. 2016;8(3):163.
Whiteside MA, Heimburger DC, Johanning GL. Micronutrients and cancer therapy. Nutr Rev. 2004;62(4):142-147.
Freites-Martinez A, Shapiro J, van den Hurk C, et al. Hair disorders in cancer survivors. J Am Acad Dermatol. 2019;80(5):1199-1213.
Freites-Martinez A, Shapiro J, Goldfarb S, et al. Hair disorders in patients with cancer. J Am Acad Dermatol. 2019;80(5):1179-1196.
Cuperus E, Leguit R, Albregts M, Toonstra J. Post radiation skin tumors: basal cell carcinomas, squamous cell carcinomas and angiosarcomas. A review of this late effect of radiotherapy. Eur J Dermatol. 2013;23:749-757.
Titeca G, Poot F, Cassart D, et al. Impact of cosmetic care on quality of life in breast cancer patients during chemotherapy and radiotherapy: an initial randomized controlled study. J Eur Acad Dermatol Venereol. 2007;21:771-776.
Dreno B, Bensadoun RJ, Humbert P, et al. Algorithm for dermocosmetic use in the management of cutaneous side-effects associated with targeted therapy in oncology. J Eur Acad Dermatol Venereol. 2013;27:1071-1080.
Lacouture ME. Dermatologic Principles and Practice in Oncology: Conditions of the Skin, Hair, and Nails in Cancer Patients. New York, NY: John Wiley & Sons; 2014:430.
Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane. J Am Acad Dermatol. 2015;72:203-218.
Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A. Cutaneous adverse effects of targeted therapies: Part II: inhibitors of intracellular molecular signaling pathways. J Am Acad Dermatol. 2015;72(2):221-236; quiz 237-8.
Cardone M, Caro G, Amorosi B, et al. Capillaroscopy: a new application for the evaluation of vascular side-effects induced by chemotherapy. G Ital Dermatol Venereol. 2020. https://doi.org/10.23736/S0392-0488.20.06401-9. [Epub ahead of print].